Literature DB >> 18077132

Fetal exposure to isotretinoin-an international problem.

Facundo Garcia-Bournissen1, Lilach Tsur, Lee H Goldstein, Arthur Staroselsky, Marina Avner, Farhan Asrar, Matitiahu Berkovitch, Gianluca Straface, Gideon Koren, Marco De Santis.   

Abstract

BACKGROUND: Isotretinoin is a known teratogen. Pregnancy prevention programs aimed at minimizing isotretinoin exposure in pregnancy have been implemented in North America with limited success.
OBJECTIVE: To compare the management of fetal risk of isotretinoin in three countries, including information given to women, implementation of contraceptive methods, and pregnancy outcomes.
METHODS: Pregnant women exposed to isotretinoin who called teratogen information services (TIS) in Israel, Italy and Canada between July 1998 and October 2006 were interviewed at the time of initial consultation and after the expected day of delivery.
RESULTS: Fifty-three pregnant women exposed to isotretinoin contacted the TIS. Only 41% reported using a birth control method. Just one patient reported using two different forms. Forty-five percent of exposed pregnancies were terminated before delivery and 22% delivered healthy babies. Two babies were born with malformations.
CONCLUSIONS: Since isotretinoin-exposed pregnancies still occur, there is a need for more effective strategies, which should take into account the cultural differences.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18077132     DOI: 10.1016/j.reprotox.2007.10.005

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN: 0890-6238            Impact factor:   3.143


  8 in total

1.  Isotretinoin use and compliance with the Dutch Pregnancy Prevention Programme: a retrospective cohort study in females of reproductive age using pharmacy dispensing data.

Authors:  Martina Teichert; Loes E Visser; Mark Dufour; Eline Rodenburg; Sabine M J M Straus; Peter A G M De Smet; Bruno H Ch Stricker
Journal:  Drug Saf       Date:  2010-04-01       Impact factor: 5.606

Review 2.  Pregnancy and isotretinoin therapy.

Authors:  June Seek Choi; Gideon Koren; Irena Nulman
Journal:  CMAJ       Date:  2013-01-07       Impact factor: 8.262

3.  Perspectives of primary care clinicians on teratogenic risk counseling.

Authors:  Eleanor Bimla Schwarz; Aimee Santucci; Sonya Borrero; Aletha Y Akers; Cara Nikolajski; Melanie A Gold
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2009-10

4.  Isotretinoin exposure during pregnancy: assessment of spontaneous reports in France.

Authors:  Elisabeth Autret-Leca; Carmen Kreft-Jais; Elisabeth Elefant; Hawaré Cissoko; François Darrouzain; Lamiae Grimaldi-Bensouda; Sarah Attia; Annie Pierre Jonville-Béra
Journal:  Drug Saf       Date:  2010-08-01       Impact factor: 5.606

5.  Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy.

Authors:  David Henry; Colin Dormuth; Brandace Winquist; Greg Carney; Shawn Bugden; Gary Teare; Linda E Lévesque; Anick Bérard; J Michael Paterson; Robert W Platt
Journal:  CMAJ       Date:  2016-04-25       Impact factor: 8.262

6.  The rates of major malformations after gestational exposure to isotretinoin: a systematic review and meta-analysis.

Authors:  Eun Jeong Choi; NaeRy Kim; Ho-Seok Kwak; Hae Ji Han; Kyoung-Chul Chun; Young-Ah Kim; Jae-Whoan Koh; Jung Yeol Han; Sung Hong Joo; Ji Sung Lee; Gideon Koren
Journal:  Obstet Gynecol Sci       Date:  2021-03-17

7.  Non-compliance with pregnancy prevention recommendations for isotretinoin in Korea between 2019-2020.

Authors:  Eun Jeong Choi; Jung Yeol Han
Journal:  Obstet Gynecol Sci       Date:  2021-01-08

8.  Knowledge of community pharmacists about the risks of medication use during pregnancy in central region of Saudi Arabia.

Authors:  Ziyad Alrabiah; Mohamed N Al-Arifi; Sultan M Alghadeer; Syed Wajid; Ali AlQahtani; Naif Almotari; AbdAllh AlHwerani; Salmeen D Babelghaith
Journal:  Saudi Pharm J       Date:  2017-05-25       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.